Biopharmaceutical Research on the Choice of a Non-Steroidal Anti-Inflammatory Agent in the Development of Combination Gel for Mastopathy Therapy

The study aimed to identify a suitable non-steroidal anti-inflammatory drug (NSAID) for developing a combination gel to treat mastopathy and prevent breast cancer. Using literary analysis, marketing research, and biopharmaceutical methods in vitro, indometacin was selected as the active pharmaceutical ingredient (API) due to its pharmacological activity. The study established the concentration of indometacin in the gel formulation. This research was significant given the high incidence of breast cancer, with over 1.7 million women diagnosed annually worldwide and a substantial number in Ukraine, highlighting the need for effective preventive treatments.